BridgeMD
New treatment option for Basal Cell Carcinoma
Official title Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
ClinicalTrials.gov ID: NCT05561634
What this study is testing
What is Vismodegib?
Vismodegib is an investigational medicine, being studied as a potential treatment for basal cell carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient over 18 years
- Locally advanced non-recurrent BCC in complete response after first course of SHHi
- Complete response has to be confirmed histologically
- Available photography or CT scan before SHHi treatment allowing delineation of the initial tumor
You likely can't join if
- Patients with distant metastasis
- Patients with Gorlin's syndrome
- Prior radiotherapy to the region of the studied cancer that would result in overlap of radiation therapy fields
- Pregnant women
- Life expectancy less than 1 year
- Inability to receive informed consent
See the full eligibility criteria
- Patient over 18 years
- Locally advanced non-recurrent BCC in complete response after first course of SHHi
- Complete response has to be confirmed histologically
- Available photography or CT scan before SHHi treatment allowing delineation of the initial tumor
- Patients with distant metastasis
- Patients with Gorlin's syndrome
- Prior radiotherapy to the region of the studied cancer that would result in overlap of radiation therapy fields
- Pregnant women
- Life expectancy less than 1 year
- Inability to receive informed consent
- Inability to participate in the entire study
- Lack of social security coverage
- Refusal to sign consent
The study team makes the final eligibility decision.
Where it's taking place
- Lille, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.